Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092387449> ?p ?o ?g. }
- W3092387449 endingPage "336" @default.
- W3092387449 startingPage "330" @default.
- W3092387449 abstract "We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treated via a compassionate access program. Endpoints assessed included response rates, toxicities, and subsequent therapies. Progression-free survival (PFS), time to next treatment (TTNT), event-free survival (EFS), overall survival (OS), and time to best response, were assessed by Kaplan–Meier analysis. The study included 31 patients, with median age 69 years. We demonstrated ORR of 35.5% (n = 11), including 4 complete responses (13%) and 7 partial responses (23%). The predicted median OS was 10 months, with EFS of 9 months, and PFS of 9 months. Median TTNT was 8 months. Mucositis was the most commonly observed toxicity. This study – the second largest real-world cohort reported to date – underscores the importance of pralatrexate in relapsed/refractory T-cell lymphoma, as well as its acceptable toxicity profile." @default.
- W3092387449 created "2020-10-15" @default.
- W3092387449 creator A5003161213 @default.
- W3092387449 creator A5006324385 @default.
- W3092387449 creator A5011532595 @default.
- W3092387449 creator A5014849816 @default.
- W3092387449 creator A5017578251 @default.
- W3092387449 creator A5017916035 @default.
- W3092387449 creator A5021734413 @default.
- W3092387449 creator A5023742907 @default.
- W3092387449 creator A5024187241 @default.
- W3092387449 creator A5027391845 @default.
- W3092387449 creator A5030063351 @default.
- W3092387449 creator A5031193094 @default.
- W3092387449 creator A5042059010 @default.
- W3092387449 creator A5043169507 @default.
- W3092387449 creator A5045579971 @default.
- W3092387449 creator A5051174375 @default.
- W3092387449 creator A5054086574 @default.
- W3092387449 creator A5062199628 @default.
- W3092387449 creator A5062642624 @default.
- W3092387449 creator A5065225093 @default.
- W3092387449 creator A5065425473 @default.
- W3092387449 creator A5069340852 @default.
- W3092387449 creator A5071287627 @default.
- W3092387449 creator A5075481228 @default.
- W3092387449 creator A5079253852 @default.
- W3092387449 creator A5082805908 @default.
- W3092387449 creator A5086184401 @default.
- W3092387449 creator A5086475162 @default.
- W3092387449 creator A5091396091 @default.
- W3092387449 date "2020-10-07" @default.
- W3092387449 modified "2023-10-01" @default.
- W3092387449 title "Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study" @default.
- W3092387449 cites W1484238615 @default.
- W3092387449 cites W1894775174 @default.
- W3092387449 cites W1983559722 @default.
- W3092387449 cites W2000940176 @default.
- W3092387449 cites W2045009458 @default.
- W3092387449 cites W2049867368 @default.
- W3092387449 cites W2115845791 @default.
- W3092387449 cites W2131809889 @default.
- W3092387449 cites W2145078955 @default.
- W3092387449 cites W2146112074 @default.
- W3092387449 cites W2161724501 @default.
- W3092387449 cites W2171873783 @default.
- W3092387449 cites W2211739901 @default.
- W3092387449 cites W2223042854 @default.
- W3092387449 cites W2310716991 @default.
- W3092387449 cites W2494190187 @default.
- W3092387449 cites W2505138627 @default.
- W3092387449 cites W2558528113 @default.
- W3092387449 cites W2737711135 @default.
- W3092387449 cites W2743972778 @default.
- W3092387449 cites W2891990978 @default.
- W3092387449 cites W2903308035 @default.
- W3092387449 cites W3034587650 @default.
- W3092387449 doi "https://doi.org/10.1080/10428194.2020.1827241" @default.
- W3092387449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33026266" @default.
- W3092387449 hasPublicationYear "2020" @default.
- W3092387449 type Work @default.
- W3092387449 sameAs 3092387449 @default.
- W3092387449 citedByCount "5" @default.
- W3092387449 countsByYear W30923874492021 @default.
- W3092387449 countsByYear W30923874492022 @default.
- W3092387449 countsByYear W30923874492023 @default.
- W3092387449 crossrefType "journal-article" @default.
- W3092387449 hasAuthorship W3092387449A5003161213 @default.
- W3092387449 hasAuthorship W3092387449A5006324385 @default.
- W3092387449 hasAuthorship W3092387449A5011532595 @default.
- W3092387449 hasAuthorship W3092387449A5014849816 @default.
- W3092387449 hasAuthorship W3092387449A5017578251 @default.
- W3092387449 hasAuthorship W3092387449A5017916035 @default.
- W3092387449 hasAuthorship W3092387449A5021734413 @default.
- W3092387449 hasAuthorship W3092387449A5023742907 @default.
- W3092387449 hasAuthorship W3092387449A5024187241 @default.
- W3092387449 hasAuthorship W3092387449A5027391845 @default.
- W3092387449 hasAuthorship W3092387449A5030063351 @default.
- W3092387449 hasAuthorship W3092387449A5031193094 @default.
- W3092387449 hasAuthorship W3092387449A5042059010 @default.
- W3092387449 hasAuthorship W3092387449A5043169507 @default.
- W3092387449 hasAuthorship W3092387449A5045579971 @default.
- W3092387449 hasAuthorship W3092387449A5051174375 @default.
- W3092387449 hasAuthorship W3092387449A5054086574 @default.
- W3092387449 hasAuthorship W3092387449A5062199628 @default.
- W3092387449 hasAuthorship W3092387449A5062642624 @default.
- W3092387449 hasAuthorship W3092387449A5065225093 @default.
- W3092387449 hasAuthorship W3092387449A5065425473 @default.
- W3092387449 hasAuthorship W3092387449A5069340852 @default.
- W3092387449 hasAuthorship W3092387449A5071287627 @default.
- W3092387449 hasAuthorship W3092387449A5075481228 @default.
- W3092387449 hasAuthorship W3092387449A5079253852 @default.
- W3092387449 hasAuthorship W3092387449A5082805908 @default.
- W3092387449 hasAuthorship W3092387449A5086184401 @default.
- W3092387449 hasAuthorship W3092387449A5086475162 @default.
- W3092387449 hasAuthorship W3092387449A5091396091 @default.
- W3092387449 hasConcept C121332964 @default.
- W3092387449 hasConcept C126322002 @default.